Advertisement

 

 

Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections.

Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections.
Author Information (click to view)

Ng SMS, Sioson JSP, Yap JM, Ng FM, Ching HSV, Teo JWP, Jureen R, Hill J, Chia CSB,


Ng SMS, Sioson JSP, Yap JM, Ng FM, Ching HSV, Teo JWP, Jureen R, Hill J, Chia CSB, (click to view)

Ng SMS, Sioson JSP, Yap JM, Ng FM, Ching HSV, Teo JWP, Jureen R, Hill J, Chia CSB,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2017 10 10() doi 10.1007/s10096-017-3114-5

Abstract

The global emergence of carbapenem-resistant Enterobacteriaceae (CRE) presents a significant clinical concern, prompting the WHO to prioritize CRE as a top priority pathogen in their 2017 global antibiotic-resistant bacteria priority list. Due to the fast-depleting antibiotic arsenal, clinicians are now resorting to using once-abandoned, highly toxic antibiotics such as the polymyxins and aminoglycosides, creating an urgent need for new antibiotics. Drug repurposing, the application of an approved drug for a new therapeutic indication, is deemed a plausible solution to this problem. A total of 1,163 FDA-approved drugs were screened for activity against a clinical carbapenem- and multidrug-resistant E. coli isolate using a single-point 10 μM assay. Hit compounds were then assessed for their suitability for repurposing. The lead candidate was then tested against a panel of clinical CREs, a bactericidal/static determination assay, a time-kill assay and a checkerboard assay to evaluate its suitability for use in combination with Tigecycline against CRE infections. Three drugs were identified. The lead candidate was determined to be Zidovudine (azidothymidine/AZT), an oral anti-viral drug used for HIV treatment. Zidovudine was shown to be the most promising candidate for use in combination with Tigecycline to treat systemic CRE infections. Further experiments should involve the use of animal infection models.

Submit a Comment

Your email address will not be published. Required fields are marked *

11 + thirteen =

[ HIDE/SHOW ]